

Review Paper

ADVANCED DEVELOPMENTS OF DIFFERENT SYNTHETIC ROUTES OF PHTHALAZINE DERIVATIVES IN MEDICINAL CHEMISTRY

Abstract –

In this review paper the different methods are highlighted that are used for the synthesis of phthalazine derivatives. They are used as building blocks for the heterocyclic compounds. These building blocks are very useful in medicinal chemistry for the research work in the development of new molecule. Those molecules that have most potent and effective in pharmacological responses. In such a way it provides a new pathway for the researches.

Keywords: Phthalazine, Phthalainone, Thiaolo, phthalic anhydride.

Introduction –

Phthalazine is a nitrogen containing compounds and due to their heterocyclic structure it plays an important role in the development of different types of heterocyclic derivatives (Mohamed Sayed et al., 2017).

The chemistry of Phthalazine derivatives increased the interest due to their chemotherapeutic application. These types of ring system are widely used in organic chemistry as intermediate for the synthesis of numerous compounds (Xu et al., 2004).


On the other hand phthalazine derivatives were studied as bioactive compounds. They possess remarkable biological activity such as anticonvulsant (Quan et al., 2009; Zhang et al., 2009), cardio tonic (Nomato et al., 1990), antihypertensive (Hoffman et al., 2006), antitumor (Sung et al., 2004; Haider et al., 2007), antidiabetic (Madhavan et al., 2001), anti-inflammatory (Dogruer et al., 2004; Sun et al., 2010), antimicrobial (Shetgiri et al., 2005), antioxidant (Bayoumi et al., 2014), PDE IV Inhibitors (Haack et al., 2005), vasorelaxant (Vatanave et al., 1998), antithrombotic (Johnson et al., 2003) etc.

Therefore a variety of methods has been reported for the synthesis of phthalazine derivatives. In this review paper it is tried to compile the different synthetic routes for the synthesis of phthalazine containing derivatives.


Synthesis of Phthalazine derivatives –

In 2004 Robert W. Carling et al., reported that 3- phenyl – 6 - (2 pyridyl) methoxy -1, 2, 4-triazolo (3,4 - a) phthalazines and analogues have γ affinity γ – aminobutyric acid.

32 A benzodiazepine receptor ligands with α_2 , α_3 and α_5 subtype binding selectivity over α_1 are
 33 synthesized from different synthetic routes:-




34
 35 Reagents: (i) 4-methoxy benzoyl chloride, Et_3N , 1,4-dioxane, room temp; (ii) DMF, reflux (iii) NaH, DMF, Ph_2Br 100
 36 temp.



37
 38 Reagents: (i) benzoyl chloride, Et_3N , 1,4-dioxane, room temp; (ii) DMF, reflux (iii) NaH, DMF, PhCH_2Br , 100 temp (iv)
 NaH, DMF, CH_3I (v) NaH, DMF, RCH_2Br or RCH_2Cl .

scheme-3




39

40

Reagents: (i) PhCONHNH₂, Et₃N, Diaxone, reflux; (ii) ROH, NaH, DMF; (iii) R₁CONHNH₂, Et₃N, Xylene, Reflux; (iv) R₁COCl, Et₃N, Diaxone, reflux.

scheme-4




41

42

Reagents: (i) NH₂NH₂.H₂O, AcOH, NaOAc, reflux; (ii) POCl₃, reflux; (iii) PhCONHNH₂, Et₃N, xylene, reflux; (iv) chromatography; (v) ROH, NaH, DMF.

43 In 2009 Lei Zhang et al., synthesized a new series of 6 – alkoxy – (1, 2, 4,) triazolo (3, 4 -a)
 44 phthalazines by using a solution of starting material (compound a) that is 1, 4
 45 dichlorophthalazine reacted with formic hydrazide in the presence of xylene which is further
 46 reacted with appropriate alcohol and substituted phenol to produce various phthalazine
 47 derivatives.

48



49
50
51
52

5c - C ₆ H ₅	5j - C ₁₀ H ₇	5q - C ₃ H ₇
5d - C ₆ H ₄ (O-CH ₃)	5k - C ₆ H ₄ (o-OCH ₃)	5r - n-C ₄ H ₉
5e - C ₆ H ₄ (m-CH ₃)	5l - C ₆ H ₄ (p-OCH ₃)	5s - n-C ₆ H ₁₃
5f - C ₆ H ₄ (p-CH ₃)	5m - C ₆ H ₄ (p-NO ₂)	5t - nC ₇ H ₁₅
5g - C ₆ H ₄ (p-F)	5n - C ₆ H ₄ (p-NH ₂)	5u - nC ₈ H ₁₇
5h - C ₆ H ₄ (p-Cl)	5o - CH ₃	5v - nC ₁₀ H ₂₁
5i - CH ₂ C ₆ H ₃ (2,4-Cl ₂)	5p - C ₂ H ₅	5w - nC ₅ H ₁₁


53
54
55

Synthesis route of compounds **5c-5w**

56 In 2011 Chingxiet et al., synthesized a new series of 6 – alkoxy (1, 2, 4) triazolo (3, 4 - a)
57 phthalazine – 3 (2H) one derivative by using as starting material appropriate 1- chloro- 4 –
58 alkoxy phthalazine with methyl hydrazine carboxylate. 1 chloro – 4 – alkoxy phthalazine
59 synthesized from phthalic anhydride reacted with hydrazine hydrate in ethanol to yield 2, 3
60 dihydrophthalazine 1, 4 dione.

61

Scheme-6



62

7d = n-C ₄ H ₉	7j = -C ₆ H ₅	7p = -C ₆ H ₄ (4-Br)
7e = n-C ₅ H ₁₁	7k = -C ₆ H ₄ (4-F)	7q = -C ₆ H ₄ (2-CH ₃)
7f = n-C ₆ H ₁₃	7l = -C ₆ H ₄ (2-Cl)	7r = -C ₆ H ₄ (3-CH ₃)
7g = n-C ₇ H ₁₅	7m = -C ₆ H ₄ (3-Cl)	7s = -C ₆ H ₄ (4-CH ₃)
7h = n-C ₈ H ₁₇	7n = -C ₆ H ₄ (4-Cl)	7t = -C ₆ H ₄ (2-OCH ₃)
7i = n-C ₁₀ H ₂₁	7o = -C ₆ H ₃ (2,4-Cl ₂)	7u = -C ₆ H ₄ (4-OCH ₃)

63

64

Synthesis route of compounds 7d-7u

65

2,3 dihydrophthalazine 1,4 dione further reacted with phosphorous oxy chloride to give 1,4 di chlorophthalazine which is further reacted with appropriate alkanol and substituted phenol in dimethyl formamide that give different derivatives (4a – 4r). These compounds reacted with methyl hydrazine carboxylate in the presence of dimethyl sulfoxide that give final series of 6-alkoxy (1,2,4) triazolo (3,4-a) phthalazine- 3(2H)-one (Cheng –Xi et al., 2011).

69

70

In 2007 Mohamed Sayed et al., synthesized a new series of phthalazine derivatives by using chloro - 4 - (4 - phenoxyphenyl) phthalazine as a starting material, In this synthesis process an equimolar amount of chlorophthalazine (0.01 mmol) and active methylene compound (0.01 mmol) was heated under reflux for 6 hours and then the reaction mixture was poured into ice/ H₂O. The obtained solid product was collected and finally wash with appropriate solvent to give

71

72


73

74

75

derivatives.

Scheme-7




76

77 For the synthesis of 2 – (4 – (4 phenoxyphenyl) phthalazine – 1 – yl) – malononitrile, they have
 78 using an eqimolor amount of chloro phthalazine (0.01 mol) and ethy----- in ethanol containing
 79 sodium ethoxide was heated under reflux for 6 hours and then reaction mixture was poured into
 80 ice/H₂O. The solid was collected and wash with proper solvent to give respective derivation.

81 A mixture of compound (2-(4-(4-phenoxyphenyl) phthalazin-1-yl)malononitrile and ethyl 2-
 82 cyano-2-(4-(4-phenoxyphenyl)phthalain-1yl)acetate (0.01mol) and hydrazine hydrate (0.01 mol)
 83 in methanol (20 ml) was heated under reflux for 6 hours then allowed to cool and then the
 84 precipitated solid was collected by filtration and recrystallized by using proper solvent. (8a,8b)


scheme-8



85

86

Scheme-9



87


88 Synthesis of 4- (4 - (4- phenoxyphenyl) phthalazine - 1- yl) 4H - pyrazole - 3, 5 di - amine.
 89 Mohamed Sayed et al., in 2017 developed a new series of heterocyclic derivatives that exhibited
 90 also other pharmacological activity like antitumor and antioxidant activities.

91 In this scheme (9) chlorophthalazine react with benzoylhydrazine under reflux in the presence of
 92 n-butanol give 6 - (4 - phenoxy phenyl) - 3 phenyl - (1, 2, 4) triazolo (3, 4-a) phthalazine (9a).
 93 This is further treated with sodium azide give (9b). In this scheme chlorophthalazine treated with
 94 P - anisidine give phthalazine derivatives (9c). Further chlorophthalazine fusion with ammonium
 95 acetate gives amino phthalazine (9d). When chlorophthalazine react with thiosemicarbozone and
 96 give amino triazolophthalazine derivatives (9e). In this reaction chlorophthalazine reacted with
 97 hydrazine hydrate in ethanol to give 1 - hydrazinyl - 4 - (4 - phenoxyphenyl) phthalazine(9f).
 98

99 In 2015 El Azm et al., given a review in that he has describe different synthetic route for the
 100 synthesis of substituted phthalazine derivatives.

101


102 Phthalazinones were synthesized by using phthalic anhydride as a starting material in the
 103 following schemes.



104

105 For the synthesis of phthalazinone derivatives reactant used phthalic anhydrides with hydrazine
 106 hydrates in the presence of acetic acid.

Scheme-11




107

108 Reagents: (a)CHCl₃, reflux, 5hr, (b)hydrazinehydrate, EtOH, addition at room temp, reflux, 2hr

109

110 In this scheme(12) phthalic anhydride and aromatic hydrocarbons in the presence of anhydrous
 111 aluminium chloride give intermediate which is further treated with hydrazine hydrates and alkyl
 112 substituted hydrazine give the phthalazine (2H) -1 – one derivatives.




113


Synthesis of phthalain(2H)-1-one

114 Kirill et al in 2004 given the cyclization of 2 – nitro – 5 – chloro phenyl hydrazine when reacted
 115 with acylbenzoic acids. This reaction derived 2 – (2 – nitro – 5 – chlorobenzene) – 4 –
 116 substituted phthalazine – 1 – ones derivatives (13a).

Scheme-13




117
 118 Luikacs and Siming G. et al in 2009 describe a different pathway for the synthesis of phthalazine
 119 derivatives by using benzophenone with chromium oxide in the mixture of acetic acid anhydride
 120 and sulphuric acid give intermediate which is further react with hydrazine hydrate in refluxing
 121 ethanol give derivative (14 a)



122
 123
 124 In this synthesis 3 – methoxy benzoic acid was used as a starting material undergoes
 125 chloroformylation and then radical bromination of next intermediate which is favour for next
 126 derivatives to improve their yield.


Scheme-15



127

128 Reaction of phthaloyl chloride with N-methyl acetophenone hydrazones leads to the formation of
 129 phthalazine derivative(15-a).

Scheme-16




130

131 a-benzoxazin-4-one, b,e- 4-aryl-1(2-H)phthalazinone, c-bis-phthalazinone, d-4-aryl-2-
 132 (4methylphenyl)phthalazinones

133 In the condensation reaction of phthalimids with hydrazine hydrate, aromatic aldehyde and malononitrile
 134 or ethyl cyano acetate catalysed by NiCl₂.6H₂O give derivative of phthalazine dione(17-a) SCHEME-17


scheme-17



135 synthesis of 1H-Pyrazolo[1,2-b]phthalazin-5,10-dione derivative

136 Ghahremanadeh et al 2008 synthesized phthalazines. in this reaction phthalhydrazide and
 137 acetylene dicarboxylates in the presence of N-heterocycles give the derivatives -18a,18-b and 18-
 138 c.(scheme-18)


scheme-18 reaction of phthalhydrazide with acetylene dicarboxylates.



140 A. A. Aly et al in 2005 focus on the synthesis of s – triazolo (3, 4 -a) phthalazine by using as a
 141 reactant. 1- chloro – 4 – phenoxathin – 2 yl – phthalazine and hydrazine hydrate in ethanol give
 142 the 1 – hydrazine – 4 –phenoxathiin - 2 – yl – phthalazine(1).(used as a starting material for the
 143 reaction)

144 Synthesis of (1) with aliphatic acids (formic and acetic acid) give 6 – phenoxathiin – 2 –yl – (1,
 145 2, 4) triazolo (3, 4 - a) phthalazine (2a) and 3 methyl – 6 –phenoxathiin – 2yl – (1, 2, 4) triazolo
 146 (3, 4 - a) – phthalazine.

scheme-19




147

148

reagents: i-RCOOH ii-RC(COOEt)₃ iii-PhCOOH iv-RCOCl v-POCl₃ vi-NH₂CONH₂ vii-CS₂ viii-CH₃I

scheme-20




149

150 In this scheme(20) 1 taken as a starting material that react with benzyl isothiocyanate in boiling

151

ethanol give derivatives 20-a,20-b.

scheme-21




152

153 In 2010 X. Y Sin et al synthesized some novel 6 alkoxy (phenoxy) – (1, 2, 4) triazolo (3, 4 - a)
 154 phthalazine – 3 – amino derivatives. Phthalic anhydride taken as starting material which reacted
 155 with hydrazine hydrate in ethanol to yield 2,3-dihydrophthalazine-1,4-dione (22-b), which
 156 reacted further with the refluxing with phosphorus oxychloride (POCl_3) that give 1,4
 157 dichlorophthalazine (22-c). Compound (22-c) further reacted f with hydrazine hydrate in tetra
 158 hydro furan(THF) to produce compound (1-hydrazine-4-chlorophthalazin). Then, 6-chlorom-
 159 [1,2,4]triazolo[3,4-a]phthalazine-3-amine 5 was prepared by cyclising compound 4 with

160 cyanogene bromide in the presence of sodium carbonate . Finally, compound (22-e) reacted with
 161 appropriate alkanol or substituted phenol to produce the 6-alkoxy(phenoxy)-[1,2,4]triazolo[3,4-
 162 a] phthalazine-3-amine derivatives (22a-22u).scheme-22

scheme-22




163
 164

165

166 In 2014 Waleed et al., synthesized new phthalazine derivative in the given scheme.

167 Phthalic anhydride used as a starting material for such type of derivative which produces 4
 168 hydroxy – 2 – phenylphthalazine - 1 – (2H) one (1) was converted into potassium salts (2) in the
 169 presence of KOH in isopropyl alcohol and vigorously stirred than a clear solution is obtained that
 170 is potassium 4 – oxo – 3 – phenyl -3, 4 – dihydrophthalazin – 1 - olate.

scheme-23



171

172 reagents; (i)PhNHNH₂,H₂O,CH₃COOH,HCl, reflux,10hr. (ii) KOH, isopropyl,stirring,1hr;(iii)ClCH₂COOH,ethanol
173 (iv)ethanol,H₂SO₄,reflux, 24hr(vNHNH₂,H₂O,ethanol,reflux,8hr)

174


175 A compound (23-b) reacted with chloroacetic acid (10 m mol) and add absolute ethanol (25 ml)
176 with continuous stirring 10 hours with reflux assembly. After the completion of process resulted
177 compound was collected. A compound (23-c) (10 m mol) absolute ethanol (50 ml) and conc.
178 H₂SO₄ (1ml) was refluxed for 24 hours then allow to cool at room temp. and then in ice water.
179 5% of sodium bicarbonate cold solution was prepared and added until effervescence ceased.

180 Obtained solid was collected after filtration it is added in sodium bi carbonate solution and
181 stirred for removing remains unreacted acid at the end of procedure. Product was collected and
182 washed with cold water.

183

184 Compound (23-d) (10 m mol) and hydrazine hydrate (5ml) in ethanol (25 ml) was refluxed for 8
 185 hours than precipitated was collected after filtration washed with ethanol and dried for collection
 186 of product (23-e).


187 T. Haack et al., in 2005 given the study of some 6 – methoxy – 1, 4 disubstituted derivatives that
 188 have PDE IV inhibitors properties. In the following scheme they are synthesized.



189 reagents;(i) acetic anhydride,toluene,reflux,10hr (ii) 2-bromothiaole,LDA,2 hr (iii) hydrazine
 190 hydrate,MeOH,AcOH,reflux, 6hr (X=H,X=Cl)

191

192



193

194

195

196 Street et al., 2004 synthesized 3 – heterocyclyl – 7, 8, 9, 10 tetrahydro – (7, 10 ethano) – 1, 2, 4 –
 197 triazolo (3, 4 - a) phthalazine ring was found as showing excellent binding selectivity & oral
 198 bioavailability for GABA receptor inverse agonist 3 – (5 – methyl isoxazol – 1 -3 - yl) 6 – (2
 199 - pyridyl) methoxy – 1, 2, 4 triazolo (3, 4 - a) phthalazine (43) provide new therapeutic
 200 alzheimer’s disease with greater therapeutic window & fewer side effect than to currently
 201 available drugs in market. 1, 4 di chloro phthalazine (20gm, 0.100 mol) was reacted with boiling
 202 solution of hydrazine monohydrate (37.3ml, 0.765 mol) in ethanol (500ml) and the mixture of
 203 this heated at reflux for 30 min, cool the mixture and collected the product by filtration and wash
 204 with ether.


205

206

207

208

scheme-25



209

210

Reagents: i) 5-methylisoxazole-3-carboxylic acid, bis(2-oxo-3-oxazolidinyl)phosphonic chloride, triethylamine, DCM ii) xylene, $\text{NEt}_3 \cdot \text{HCl}$, reflux, 16hr. iii) pyridine-2-methanol, NaH, DMF

211

212

Conclusion –

213 Phthalazine is a heterocyclic compound which is obtained from different reactants like Phthalazine

214 phthalate, Hydrazine hydrate etc. When phthalazine is incorporated with different functional rings and

215 fused components gives pharmacologically active compound that have less side effect with potent

216 action. With the help of found literature the newer activities of different phthalazine derivatives are

217 more beneficiary than the older compound. In this review paper it has been tried to provide best

218 possible synthetic routes for the development of different derivative of phthalazine moiety that will

219 provide a platform to the researchers.

220

221

222

223

224

225

REFERENCES

226
227

1. Nahed, F., Ghaffar, A. E., Mona, A., Ghanem, H. M., Zaki, H. M., 2011. *Journal of American Science*. 7, 771-781.

228

2. Aziz, M.A., Youssef, A., Essam, I., 2012. *Turk. J. Chem.* 36, 347-366.

229

3. Quan, Z. S., Sun, X. Y., Guan, L. P., 2009. *Chem. Biol. Drug Des.* 73, 313-319.

230

4. Gschwind, H. P., Jalava, T., 2006. *Drug Metabolism and Disposition.* 34, 1817.

231

5. Zhang, S., Zhao, Y., Liu, Y., Chen, D., Lan, W., Zhao, Q., Dong, C., Xia, L., Gong, P., 2010. *Eur. J. Med. Chem.* 45, 3504.

232

233

6. Lebsack, A. D., Gunzner, J., Wang, B., Pracitto, R., Schaffhauser, H., Santini, A., Aiyar, J., Bezverkov, R., Munoz, B., Liuc, W. Venkatraman, S., 2004. *Bioorg. & Med. Chem. Lett.* 14, 2463.

234

235

236

7. Jhang, L., Guan, L.P., Sun, X. Y., 2009. *Chem Biol Drug Des.* 73, 313-319.

237

8. Shan, Q. Z., Xi, W.C., Nan, L.F., 2011. *Asian journal of chemisrty.* 23, 127-131.

238

9. Sayed, M., Rafaat, R., 2017. *Der Pharma Chemica.* 9, 30 – 38.

239

10. El Azm, F. S. A., Mahmoud, M.R., Hekal, M.H., 2015. *Organic Chemisrty Current Resaerch.* 4, 1-12.

240

241

11. Aly, A. A., GadEl-Karim, I. A., 2005. *Phosphorus, Sulfur, and Silicon.* 180, 1997-2011.

242

12. Carling, R. W., Moore, K. W., Street, L. J., Wild, D., Isted, C., Leeson, P. D., Thomas, S., O'Connor, D., McKernan, R. M., Quirk, K., Cook, S. M., Atack, J. R., Wafford, K. A., Thompson, S. A., Dawson, G. R., Ferris, P., Castro, J. L., 2004. *J. Med. Chem.* 47, 1807.

243

244

245

13. Bayoumi, W.A., Barghash, A.M., Gineinah, M.M., Massoud, M.A., 2014. *Der. pharma chemica.* 6, 89-102.

246

247

14. Haack, T., Fattori, R., Pellacini, F., Fronza, G., Ganazzoli, F., 2005. 13, 4425-4433.

248

15. De, P., Yoya, G. K., Constant, P., Bedos-Belval, F., Duran, H., Saffon, N., Daffe, M., Baltas, M., 2011. *J. Med. Chem.* 54, 1449.

249

250

16. Sun, X., Hua, C., Deng, X., Wei, C., Sun, Z., Quan, Z., 2010. *Eur. J. Med. Chem.* 45, 4807.

251

252

17. Orvieto, F., Koch, U., Matassa, V. G., Muraglia, E., 2003. *Bioorg. Med. Chem. Lett.* 13, 2745.

253

254

18. Johansson, P.O., Jansson, K., Vrang, L. Hamelink, E., Hallberg, A., Rosenquist, A., Samuelsson, B. 2006. *Bioorg. Med. Chem.* 14, 5136.

255

256

257

19. Ortqvist, P., Peterson, S. D., kerblom, E. A., Gossas, T., Sabnis, Y. A., Fransson, R., Lindeberg, G. Danielson, U. H., Karlen, A., A. 2007. *Bioorg. Med. Chem.* 15, 1448.

258

- 259 **20.** Jacobson, I. C., Reddy, P. G., Wasserman, Z. R., Hardman, F. D., Covington, M. B.,
260 Arner, E. C., Copeland, R. A., Decicco, C. P., Magolda, R. L., 1998. *Bioorg. Med. Chem.*
261 *Letts.* 6, 837.
- 262 **21.** Sani, M., Belotti, D., Giavazzi, R., Panzeri, W., Volonterio, A., Zanda, M., 2004.
263 *Tetrahedron Letts.* 45, 1611.
- 264 **22.** Fray, M. J., Dickinson, R. P., Huggins, J. P., Occleston, N. L., 2003. *J. Med. Chem.* 46,
265 3514.
- 266 **23.** Chevallier, C., Richardson, A. D., Edler, M. C., Hamel, E. Harper, M. K., Ireland, C. M.,
267 2003. *Org. Letts.* 5, 3737.
- 268 **24.** Matsunaga, S., Fusetani, N., Konosu, S., 1985. *Tetrahedron Letts.* 26, 855.
- 269 **25.** Ryu, G., Matsunaga, S., Fusetani, N., 1994. *Tetrahedron Letts.* 35, 8251.
- 270 **26.** Nakanishi, K., 1967. *Pure Appl. Chem.* 14, 89.
- 271 **27.** Nakanishi, K., Habaguchi, K., Nakadaira, Y., Woods, M. C., Maruyama, M., Major, R.
272 T., Alauddin, M. A., Patel, R., Weinges, K., Bahr, W., 1971. *J. Am. Chem. Soc.*, 93, 3544.
- 273 **28.** Hu, L., Chen, Z., Cheng, X., Xie, Y., 1999. *Pure Appl. Chem.* 71, 1153.
- 274 **29.** Vogensen, S. B., Strmggaard, K., Shindou, H., Jaracz, S., Suehiro, M., Ishii, S., Shimizu,
275 T., Nakanishi, K., 2003. *J. Med. Chem.* 46, 601.
- 276 **30.** Mujumdar, R. B., Rama, A. V., Rao, S., Rathi, S., Venkataraman, K., 1975. *Tetrahedron*
277 *Letts.* 16, 867.
- 278 **31.** Kotake, C., Yamasaki, T., Moriyama, T., Shinoda, M., Komiyama, N., Furumai, T.,
279 Konishi, M., Oki, T., 1992. *J. Antibiot.* 45, 1442.
- 280 **32.** Chan, W. S. Hui, W. H., 1973. *J. Chem. Soc. Perkin Trans.* 1, 490.
- 281 **33.** Li, X., Djerassi, C., 1983. *Tetrahedron Letts.* 24, 665.
- 282 **34.** Giner, J. L., Djerassi, C., 1991. *Phytochemistry.* 30, 811.
- 283 **35.** Pettit, G. R., Gao, F., Sengupta, D., Coll, J. C. Herald, C. L., Doubek, D. L., Schmidt, J.
284 M., Van Camp, J. R., Rudloe, J. J., Nieman, R. A., 1991. *Tetrahedron.* 47, 3601.
- 285 **36.** Hwang, J. Y., Choi, H. and Gong, Y., 2005. *Tetrahedron Letts.* 46, 3107.
- 286 **37.** Carling, R. W., Moore, K. W., Street, L. J., Wild, D., Isted, C., Leeson, P. D., Thomas,
287 S., O'Connor, D., McKernan, R. M., Quirk, K., Cook, S. M., Atack, Wafford, J. R.,
288 Thompson, K. A., S. A., Dawson, G. R., Ferris, P., Castro, J. L., 2004. *J. Med. Chem.* 47,
289 1807.
- 290 **38.** Street, L. J., Sternfeld, F., Jolley, R. A., Reeve, A. J., Carling, R. W., Moore, K. W.,
291 McKernan, R. M., Sohal, B., Cook, S., Pike, A., Dawson, G. R., Bromidge, F. A.,
292 Wafford, K. A., Seabrook, G. R., Thompson, S. A., Marshall, G., Pillai, G. V., Castro, J.,
293 Atack, J. R., MacLeod, A. M., 2004. *J. Med. Chem.* 47, 3642.

- 294 **39.** Tarzia, G., Occelli, E., Toja, E., Barone, D., Corsico, N., Gallico, L., Luzzani, F., 1988. J.
295 Med. Chem. 31, 1115.
- 296 **40.** Sun, X. Y., Quan, Z.S., Sun, Z.G., Deng, X.Q., 2010. Eur. J. Med. Chem. 45: 4807-12.
297
- 298 **41.** Kumar, N., Singh, S., 2014. World journal of pharmacy and pharmaceutical sciences. 3, 729-
299 736.
- 300 **42.** Xu Y, Guo QX (2004) Syntheses of Heterocyclic Compounds under Microwave
301 Irradiation. Heterocycles 63: 903-974.
302
303
- 304 **43.** Al-Assar, F., Zelenin, K.N., Lesiovskaia, E.E, Benzhan, I.P., Chakchir, B.A., 2002..
305 Pharm Chem J. 36, 598-603.
306
- 307 **44.** Grasso, S., De Sarro, G., De Sarro, A., Micale, N., Zappalà, M., 2000. J Med Chem. 43,
308 2851-2859.
309
- 310 **45.** Kornet, M.J., Shackelford, G., 1999. J Heterocycl Chem. 36, 1095-1096.
311
- 312 **46.** Sivakumar, R., Kishore, Gnanasam., S, Ramachandran, S., Leonard, J.T., 2002. Eur J Med
313 Chem. 37, 793-801.
314
- 315 **47.** . Nomoto, Y., Obase, H., Takai, H., Teranishi, M., Nakamura, J., 1990. Chem Pharm Bull
316 38, 2179-2183.
317
- 318 **48.** Sung, Kim. J., Lee, H.J, Suh, M.E, Choo, H.Y, Lee, S.K., 2004. Bioorg Med Chem. 12
319 3683-3686.
320
- 321 **49.** Haider, N., Kabicher, T., Käferböck, J., Plenk, A., 2007. 12, 1900-1909.
322
- 323 **50.** . Demirayak, S., Karaburun, A.C., Beis, R., 2004. Eur J Med Chem. 39, 1089-1095.
324
- 325 **51.** Watanabe, N., Kabasawa, Y., Takase, Y., Matsukura, M., Miyazaki, K., 1998. J Med
326 Chem. 41, 3367-3372.
327
- 328 **52.** Madhavan, G.R., Chakrabarti, R., Kumar, S.K., Misra, P., Mamidi, R.N., 2001. Eur J
329 Med Chem. 36, 627-637.
330

- 331 **53.** Johnsen, M., Rehse, K., Pertz, H., Stasch, J.P., Bischoff, E.,2003. Arch Pharm
332 (Weinheim). 336, 591-597.
333
- 334 **54.** Cardia, M.C, Distinto, S., Maccioni, E., Delogu, A.,2009. J HeterocyclChem. 40, 1011-
335 1015.
336
- 337 **55.** Shetgiri, N.P., Nayak, B.K., 2005. Ind Jchem. 44B, 1267-1272.
338
- 339 **56.** Dogruer, D.S., Kupeli, E., Yesilada, E., Sahin, M.F 2004. Arch Pharm (Weinheim). 337,
340 303-310.
341
- 342 **57.** Napoletano, M., Norcini, G., Pellacini, F., Marchini, F., Morazzoni, G.,2000. Bioorg Med
343 ChemLett. 10, 2235-2238.
344
- 345 **58.** Bedoya, L.M., del Olmo, E., Sancho, R., Barboza, B., Beltrán, M., 2006. Bioorg Med
346 ChemLett.16, 4075-4079.
347
- 348